Rituximab in lupus and beyond: the state of the art

1 Hughes G  . Rituximab: an update. Lupus 2007; 16: 529–530.

2 Harris HE  . Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology 2008; 47: 224–225.

3 Albert D  Dunham J  Khan S  . Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 1724–1731.

4 Smith KG  Jones RB  Burns SM  Jayne DR  . Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970–2982.

5 Chang X  Gao JX  Jiang Q  . The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med 2005; 202: 1141–1151.

6 Valencia X  Yarboro C  Illei G  Lipsky PE  . Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579–2588.

7 Vigna-Perez M  Hernández-Castro B  Paredes-Saharopulos O  . Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8: R83.

8 Shah S  Qiao L  . Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-beta3. Eur J Immunol 2008; 38: 2488–2498.

9 Cambridge G  Isenberg DA  Edwards JC  . B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011–1016.

10 Thurlings RM  Vos K  Gerlag DM  Tak PP  . Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008; 58: 3657–3664.

11 Owczarczyk K  Hellmann M  Fliedner G  . Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 2008; 67: 1648–1649.

12 Ruiz-Irastorza G  Khamashta MA  Hunt BJ  Escudero A  Cuadrado MJ  Hughes GR  . Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164–1169.

13 Girardi G  Redecha P  Salmon JE  . Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222–1226.

14 Adamson R  Sangle S  Kaul A  Hughes GR  D’Cruz DP  . Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol 2008; 14: 359–360.

15 Isaksen K  Jonsson R  Omdal R  . Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008; 68: 554–564.